top of page
Confident female surgeon in an OR
Confident female surgeon in an OR

Optimize time.
Maximize control.

Go dropless with OMIDRIA.

OMIDRIA, as part of a dropless regimen, streamlines cataract surgery for surgeons and patients by reducing postoperative time and costs while maximizing control over medication delivery and compliance with the only FDA-approved intracameral NSAID.

96%

of OMIDRIA-treated patients had pupil diameter ≥6 mm at the start of lens implantation1,11,13,14

67.2%

reduction in use of PEDs during surgery7

21%

reduction in mean surgical time, saving over 3 1/2 minutes in pts 65 to 70 7

OMIDRIA was 4-6 times more effective in miosis prevention than either ketorolac or phenylephrine alone.15

Effectively maintains pupil dilation

and requires less use of PEDs1-8

Reduces complications

such as IFIS, CME, and breakthrough iritis7

Improves patient experience

with less pain, greater visual acuity, and fewer to no drops1,3,11,12

Why go dropless?

Postoperative cataract surgery drops place control and surgical outcomes in the hands of the patient, and create a burden for patients, surgeons and their staff.

Why go dropless with OMIDRIA?

OMIDRIA, containing intraocular ketorolac, delivers a patient-preferred, dropless cataract surgery solution as effective as a standard topical regimen.12

Portrait of a focused female surgeon preparing for surgery

OMIDRIA streamlines cataract surgery

Places control and surgical outcomes in surgeon’s hands

Delivers the only FDA-approved intracameral NSAID

Patient consulting with healthcare professional

OMIDRIAssure® — learn more about dedicated access and support for your patients

Contact us to discover more about going dropless with OMIDRIA

Patient administering eye drops

92.6%

of patients fail to properly administer eye drops16

64%

instill an incorrect amount of eye drops16

31.5%

miss their eye16

References:

  1. Omidria [prescribing information]. Bellevue, WA: Rayner Surgical Inc. April 2023.

  2. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2018;44(9):1103-1108.

  3. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Clin Ophthalmol. 2018;12:21-28.

  4. Al-Hashimi S, Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. J Cataract Refract Surg. 2018;44(8):1032-1041.

  5. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Clin Ophthalmol. 2017;11:1039-1043.

  6. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract surgery: reduction in surgical time and iris manipulation. J Cataract Refract Surg. 2019;45(4):465-469.

  7. Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. Clin Ophthalmol. 2018;12:301-305.

  8. Matossian C. Clinical and economic outcomes in cataract surgery using phenylephrine 1.0%-Ketorolac 0.3% in a real-world setting. Abstract presented at: Annual Meeting of the American Society of Cataract and Refractive Surgeons (ASCRS); April 16, 2018; Washington, DC. Course 5219.

  9. Donnenfeld ED, Shojaei RD. Effect of intracameral phenylephrine and ketorolac 1.0%/0.3% on intraoperative pain and opioid use during cataract surgery. Clin Ophthalmol. 2019;13:2143-2150.

  10. Hovanesian JA, Sheppard JD, Trattler WB, et al. Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: integrated results from 2 pivotal phase 3 studies. J Cataract Refract Surg. 2015;41:2060-206.

  11. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020;46(6):867-872.

  12. Donnenfeld ED, Hovanesian JA, Malik AG, Wong A. A randomized, prospective, observer-masked study comparing dropless treatment regimen using intracanalicular dexamethasone insert, intracameral ketorolac, and intracameral moxifloxacin versus conventional topical therapy to control postoperative pain and inflammation in cataract surgery. Clin Ophthalmol. 2023;17:2349-2356.

  13. Lindstrom RL, Loden JC, Walters TR, et al. Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification. Clin Ophthalmol. 2014;8:1735-1744.

  14. Rayner. Data on file.

  15. Donnenfeld ED, Whitaker JS, Jackson MA, Wittpenn J. Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery. J Cataract Refract Surg. 2017;43(5):597-605.

  16. An JA, Kasner O, Samek DA, Lévesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40(11):1857-1861.

  17. Wielders LHP, Schouten JSAG, Winkens B, et al, for the ESCRS PREMED Study Group. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J Cataract Refract Surg. 2018;44:429-439.

  18. Patel A, Gorrai A, Wesberry J, et al. A review of postoperative drops used in cataract surgery. American Academy of Ophthalmology, EyeWiki. October 6, 2024. Accessed: January 28, 2025.  https://eyewiki.org/A_Review_of_Postoperative_Drops_Used_in_Cataract_Surgery

  19. Rossi T, Romano MR, Lanatta E, et al. Cataract surgery practice patterns worldwide: a survey. BMJ Open Ophthalmology 2021:6(1):e00464. Published Jan 13, 2021

  20. Lindstrom RL, Galloway MS, Grzybowski A, Liegner JT. Dropless cataract surgery: an overview. Curr Pharm Des. 2017;23(4):558–564.

  21. Donnenfeld EDD. Blocking the inflammatory cascade. CRST. Accessed August 30, 2024. https://crstoday.com/articles/blocking-the-inflammatory-cascade/blocking-the-inflammatory-cascade

  22. Waterbury LD. Alternative drug delivery for patients undergoing cataract surgery as demonstrated in a canine model. J Ocular Pharmacol Ther. 2018;34(1-2):154-160.

  23. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4%plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008;146:554–560.

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.


Systemic exposure to phenylephrine may cause elevations in blood pressure.


Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.


The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.


Please see the Full Prescribing Information for OMIDRIA.


You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.


Systemic exposure to phenylephrine may cause elevations in blood pressure.


Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.


The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.


Please see the Full Prescribing Information for OMIDRIA.


You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

bottom of page